Degenerative pontine lesions in patients with familial narcolepsy

Neurologia i Neurochirurgia Polska

Volumn 44, Issue 1, 2010, Pages 21-27

  Stȩpień, Adam ^a   Staszewski, Jacek ^a   Domzał, Teofan Maria ^a   Tomczykiewicz, Kazimierz ^a   Skrobowska, Ewa ^a   Durka Kȩsy, Marta ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Familial narcolepsy; Magnetic resonance imaging; Pontine substantia nigra

Indexed keywords

MODAFINIL; OREXIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BRAIN DAMAGE; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; ELECTROENCEPHALOGRAM; EPWORTH AND STANFORD SLEEPINESS SCALE; FEMALE; HUMAN; HYPNAGOGIC HALLUCINATION; MALE; NARCOLEPSY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARASOMNIA; POLYSOMNOGRAPHY; PRESCHOOL CHILD; SCORING SYSTEM; SUBSTANTIA NIGRA;

EID: 77951283376     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3843(14)60403-5     Document Type: Article

References (30)

1. Billiard M., Cadilhac J. Narcolepsy. Rev Neurol 1985; 141: 515-527.
2. Ohayon M.M., Okun ML. Occurrence of sleep disorders in the families of narcoleptic patients. Neurology 2006; 67: 703-705.
3. Ellis M.C., Hetisimer A.H., Ruddy D.A., et al. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics 1997; 46: 410-417.
4. Hayduk R., Flodman P., Spence M.A., et al. HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy. Sleep 1997; 20: 850-857.
5. Mignot E., Lin L., Rogers W. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum. Genet 2001; 68: 686-699.
6. Kadotani H., Faraco J., Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res 1998; 8: 427-434.
7. Aldrich M.S., Prokopowicz G., Ockert K., et al. Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994; 17: 598-608.
8. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-376.
9. Thannickal T.C., Moore R.Y., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-474.
10. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brain. Nat Med 2000; 6: 991-997.
11. Nishino S., Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005; 9: 269-310.
12. D'Cruz O.F., Vaughn B.V., Gold S.H., et al. Symptomatic cataplexy in pontomedullary lesions. Neurology i994; 44: 2189-2191.
13. Plazzi G., Montagna P., Provini F., et al. Pontine lesions in idiopathic narcolepsy. Neurology 1996; 46: 1250-1254.
14. American Academy of Sleep Medicine. International classification of sleep disorders, revised: Diagnostic and coding manual. American Academy of Sleep Medicine, Chicago 2001.
15. Aldrich M.S., Chervin R.D., Malow B.A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997; 20: 620-629.
16. Bassetti C., Aldrich M.S., Quint D.J. MRI findings in narcolepsy. Sleep 1997; 20: 630-631.
17. Ellis C.M., Simmons A., Lemmens G., et al. Proton spectroscopy in the narcoleptic syndrome. Is there evidence of a brainstem lesion? Neurology 1998; 50 (2 Suppl 1): S23-S26.
18. Melberg A., Dahl N., Hetta J., et al. Neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy. Neurology 1999; 53: 2190-2192.
19. Thannickal T.C., Siegel J.M., Nienhuis R., et al. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003; 13: 340-351.
20. Boutrel B., Koob G.F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004; 27: 1181-1194.
21. Dhawan V., Healy D.G., Pal S., et al. Sleep-related problems of Parkinson's disease. Age Ageing 2006; 35: 220-228.
22. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain 2008; 131: e87.
23. Deadwyler S.A., Porrino L., Siegel J.M., et al. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007; 27: 14239-14247.
24. Fronczek R., Overeem S., Lee S.Y., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585.
25. Bubser M., Fadel J.R., Jackson L.L., et al. Dopaminergic regulation of orexin neurons. Eur J Neurosci 2005; 21: 2993-3001.
26. Drouot X., Moutereau S., Nguyen J.P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003; 61: 540-543.
27. Yasui K., Inoue Y., Kanbayashi T., et al. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006; 250: 120-123.
28. Mignot E., Lammers G.J., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562.
29. Krahn L.E., Pankratz V.S., Oliver L., et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002; 25: 733-736.
30. Eisensehr I., Linke R., Tatsch K., et al. Alteration of the striatal dopaminergic system in human narcolepsy. Neurology 2003; 60: 1817-1819.